Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Concord Drugs Ltd. Share Price
Day's Range
Day's Range
Low
₹
High
₹
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 107.74 | 432.7 |
| Expenses | N/A | N/A |
| PBT | 5.21 | 5.58 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 2.22 | 4.2 |
About Concord Drugs Ltd.
| Founded | 1995 |
|---|---|
| Managing Director | S Nagi Reddy |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,51,194.94 | 1,880.50 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,82,992.80 | 6,920.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,49,926.25 | 4,458.90 | 3,102.00 - 3,102.00 |
| Apollo Hospitals Enterprise Ltd. | 1,16,446.16 | 8,066.25 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,13,051.69 | 1,401.00 | 1,165.70 - 1,165.70 |
| Dr. Reddy's Laboratories Ltd. | 1,10,333.30 | 1,320.00 | 1,148.40 - 1,148.40 |
| Mankind Pharma Ltd. | 1,06,668.90 | 2,583.35 | 1,909.70 - 1,909.70 |
| Max Healthcare Institute Ltd. | 1,04,750.23 | 1,076.25 | 903.00 - 903.00 |
| Zydus Lifesciences Ltd. | 1,04,743.93 | 1,040.95 | 835.50 - 835.50 |
| Lupin Ltd. | 1,04,400.67 | 2,288.65 | 1,836.80 - 1,836.80 |
No Records Found
Latest News
Aarti Pharmalabs informs about conference call
Bharat Parenterals informs about transcript of earnings conference call
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Para A of Part A of Schedule III, Bharat Parenterals has informed that it enclosed a copy of transcript of Company’s Operational and Financial Performance for the Quarter and Year Ended on March 31, 2026 (Q4FY26) held on Tuesday, May 19, 2026. The transcript is also uploaded on the Company’s website at www.bplindia.in.
The above information is a part of company’s filings submitted to BSE.
Medicamen Biotech informs about board meeting
Pursuant to Regulation 29 read with Regulation 33 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’), Medicamen Biotech has informed that a Meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, May 27, 2026 at the registered office of the Company situated at 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019 to consider and approve the following business(s): 1. The Audited Financial Results of the Company (Standalone and Consolidated) for the quarter / year ended on March 31, 2026 2. To consider the recommendation of Final Dividend on Equity Shares of the Company for the financial year 2025-26, if any. 3. To consider and appoint SPB & Co, Cost Accountants, as the Cost Auditor of the company for the financial year 2026-27. 4. To consider and appoint Cheena & Associates, as the Internal Auditor of the company for the financial year 2026-27. 5. Any other business with the permission of the chair. Further, in accordance with the SEBI (Prevention of Insider Trading) Regulations, 2015 and the Company's Code of Conduct for Prevention of Insider Trading, the Trading Window for dealing in the Company's securities was closed from April 1, 2026 and will open 48 hours after the said Financial Results are declared to Stock Exchanges.
.The above information is a part of company’s filings submitted to BSE.
Aarti Pharmalabs informs about analyst meet
Aarti Pharmalabs has informed that the Company will be meeting investors and analysts (One on One and group) in 360 ONE Capital Conference - Trinity 2026 on Thursday, May 28, 2026. No unpublished price sensitive information pertaining to the Company shall be shared at the said meeting.
The above information is a part of company’s filings submitted to BSE.
Max Healthcare Institute informs about grant of stock options
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Concord Drugs Ltd. is ₹80.75 as of 2026-05-20.
The market capitalisation of Concord Drugs Ltd. is ₹106.39 as of 2026-05-20.
The 1-year return of Concord Drugs Ltd. is 48.42% as of 2026-05-20.
The P/E ratio of Concord Drugs Ltd. is 92.45 as of 2026-05-21.
The 52-week high and low of Concord Drugs Ltd. are ₹92.52 and ₹29.00, respectively, as of 2026-05-20.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
